drugset / Trial / NCT03003104

DMT210 Topical Gel in the Treatment of Acne Rosacea

NCT03003104 ↗

Phase 2 Completed 107 enrolled Dermata Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.

Timeline

Start
2017-01
Primary completion
2017-08-30
Completion
2017-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DMT210 Unknown 5 % Topical

Indications